1. McNay MB, Fleming JE. Forty years of obstetric ultrasonography 1957-1997: from A-scope to three dimensions. Ultrasound Med Biol. 1999; 25:3–56.
2. Grant SS. Options for Down syndrome screening: what will women choose? J Midwifery Womens Health. 2005; 50:211–218.
3. Chen M, Lee CP, Lam YH, Tang RY, Chan BC, Wong SF, et al. Comparison of nuchal and detailed morphology ultrasonography examinations in early pregnancy for fetal structural abnormality screening: a randomized controlled trial. Ultrasound Obstet Gynecol. 2008; 31:136–146.
4. Saltvedt S, Almström H, Kublickas M, Valentin L, Grunewald C. Detection of malformations in chromosomally normal fetuses by routine ultrasonography at 12 or 18 weeks of gestation-a randomised controlled trial in 39,572 pregnancies. BJOG. 2006; 113:664–674.
5. Timor-Tritsch IE, Fuchs KM, Monteagudo A, D'alton ME. Performing a fetal anatomy scan at the time of first-trimester screening. Obstet Gynecol. 2009; 113:402–407.
6. Cedergren M, Selbing A. Detection of fetal structural abnormalities by an 11-14-week ultrasonography dating scan in an unselected Swedish population. Acta Obstet Gynecol Scand. 2006; 85:912–915.
7. Taipale P, Ammala M, Salonen R, Hiilesmaa V. Learning curve in ultrasonographic screening for selected fetal structural anomalies in early pregnancy. Obstet Gynecol. 2003; 101:273–278.
8. Fisher J. First-trimester screening: dealing with the fall-out. Prenat Diagn. 2011; 31:46–49.
9. Rossi AC, Prefumo F. Accuracy of ultrasonography at 11-14 weeks of gestation for detection of fetal structural anomalies: a systematic review. Obstet Gynecol. 2013; 122:1160–1167.
10. Salomon LJ, Alfirevic Z, Bilardo CM, Chalouhi GE, Ghi T, Kagan KO, et al. ISUOG practice guidelines: performance of first-trimester fetal ultrasonography scan. Ultrasound Obstet Gynecol. 2013; 41:102–113.
11. Hershkovitz R, Sheiner E, Mazor M. Ultrasonography in obstetrics: a review of safety. Eur J Obstet Gynecol Reprod Biol. 2002; 101:15–18.
12. Salvesen K, Lees C, Abramowicz J, Brezinka C, Ter Haar G, Marsal K, et al. ISUOG statement on the safe use of Doppler in the 11 to 13 +6-week fetal ultrasonography examination. Ultrasound Obstet Gynecol. 2011; 37:628.
13. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. Fetal Medicine Foundation First Trimester Screening Group. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet. 1998; 352:343–346.
14. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003; 349:1405–1413.
15. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005; 353:2001–2011.
16. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasonography screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992; 304:867–869.
17. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and ultrasonography Screening Study (SURUSS). J Med Screen. 2003; 10(2):56–104.
18. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005; 25:221–226.
19. Jouannic JM, Thieulin AC, Bonnet D, Houyel L, Lelong N, Goffinet F, et al. Measurement of nuchal translucency for prenatal screening of congenital heart defects: a population-based evaluation. Prenat Diagn. 2011; 31:1264–1269.
20. Simpson LL, Malone FD, Bianchi DW, Ball RH, Nyberg DA, Comstock CH, et al. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol. 2007; 109:376–383.
21. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 2005; 192:1005–1021.
22. Cuckle H. Monitoring quality control of nuchal translucency. Clin Lab Med. 2010; 30:593–604.
23. Sahota DS, Leung WC, To WK, Chan WP, Lau TK, Leung TY. Quality assurance of nuchal translucency for prenatal fetal Down syndrome screening. J Matern Fetal Neonatal Med. 2012; 25:1039–1043.
24. D'Alton ME. Nuchal translucency quality monitoring: the transition from research to clinical care. Obstet Gynecol. 2010; 116:806–807.